Vector Consulting Group, India’s leading management consulting firm, has released an insightful report offering Indian pharmaceutical companies strategic guidance to enhance operational agility and cost efficiency in the face of dynamic challenges in the U.S. market. The analysis, titled “Pharma Vision,” provides actionable solutions to help companies boost competitiveness, ensure quality, and accelerate research and development (R&D) capabilities.

The U.S. generic drug market, valued at approximately $86.9 billion, remains the largest market for Indian generics. However, this market is characterized by fierce competition and fluctuating price dynamics. Recently, supply shortages have led to unexpected price increases for certain drugs, challenging companies to balance cost-cutting measures with growth investments.

Dr. Shelja Jose Kuruvilla, Head of Knowledge and Research at Vector Consulting Group, remarked, “Indian pharmaceutical companies with significant exposure to the U.S. market often grapple with the strategic tension between cost-cutting and pursuing growth. The current scenario, with some drugs experiencing price increases due to supply shortages, has caught companies by surprise. Many had been reducing capacities in response to margin pressures, but the real challenge lies in achieving substantial improvements in supply chain agility alongside cost efficiency.”

Key Strategies Highlighted in the Pharma Vision Report:

1. Amplifying Operational Agility: The report advocates transitioning from traditional forecast-based inventory systems to dynamic, constraint-based production models. This transformation enhances responsiveness to market changes, potentially reducing lead times by 25%-50% and lowering inventory levels by 20%-40%. Furthermore, integrating Active Pharmaceutical Ingredient (API) suppliers into the supply chain, coupled with enhanced visibility and collaboration, can lead to notable cost savings and operational efficiency.
2. Ensuring Perpetual Quality Readiness: Moving beyond inspection-based approaches, the report emphasizes embedding regulatory compliance into daily operations. Standardizing quality practices across all manufacturing sites and employing rigorous root cause analysis (RCA) can reduce invalid Out of Specification (OOS) incidents by over 70% and lab incidents by 50%-70%. This proactive approach not only minimizes compliance risks but also optimizes overall operational efficiency.
3. Building Rapid R&D Capabilities: The report outlines strategies for accelerating R&D processes, including adopting project flow management principles and defining objective capacity to manage project loads. Techniques such as ‘full kitting’ and agile short burst planning cycles can lead to a 30%-50% reduction in R&D lead times and a 50% increase in project throughput.

Also Read: Biological E. Oral Polio Vaccine Type 2 Earns WHO Pre-Qualification Status.

The Pharma Vision report provides a comprehensive roadmap for Indian pharmaceutical companies to navigate the complexities of the U.S. market, ensuring they remain agile, competitive, and ready to seize new opportunities.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!